Browse the evidence

Obesity causes insulin resistance primarily through the expansion of adipose tissue mass, which acts as an endocrine organ secreting factors like TNF-alpha, FFAs, and leptin that impair insulin signaling in muscle and liver.

Focus on reducing central adiposity, as intra-abdominal fat is more metabolically harmful than peripheral fat. This involves addressing the endocrine function of fat tissue, not just weight loss, by managing factors like free fatty acid flux and inflammatory cytokines.

Adipose tissue acts as an endocrine organ, secreting hormones like leptin and cytokines like TNF-alpha, which directly impair insulin signaling in peripheral tissues.

Understand that fat tissue is biologically active. Reducing fat mass helps by reducing the secretion of harmful hormones and cytokines, thereby improving insulin sensitivity.

Early combination therapy with metformin, a thiazolidinedione (TZD), and a GLP-1 receptor agonist (exenatide) is required to correct the multiple pathophysiological defects of type 2 diabetes and preserve beta-cell function, whereas sulfonylureas should be avoided due to progressive beta-cell failure.

If you have type 2 diabetes or pre-diabetes (IGT), waiting until your blood sugar is high to treat it is too late. The paper argues you should start a combination of lifestyle changes, metformin, a TZD (like pioglitazone), and a GLP-1 agonist (like exenatide) early. Avoid sulfonylureas as they harm your pancreas over time. The goal is to protect your beta-cells, not just lower a number.

Beta-cell function is lost by 80-85% in individuals with Impaired Glucose Tolerance (IGT), meaning significant damage occurs long before a formal diabetes diagnosis.

If you have 'pre-diabetes' (IGT), you have likely already lost 80% of your pancreas's ability to make insulin. This is not a 'wait and see' condition. You need to act now to preserve what function remains.

High leukocyte count (>=9x10^9/L) is an independent and significant predictor of cardiovascular recurrence in post-MI patients, regardless of dietary pattern.

Monitor your white blood cell count. An elevated count (>=9x10^9/L) is a strong independent risk factor for another heart event, even if you are following a heart-healthy diet. This suggests that inflammation management is a critical component of secondary prevention.

Associations between specific nutrient intakes and disease are likely secondary to differences in total caloric intake, body size, physical activity, or metabolic efficiency, rather than representing primary etiologic effects of the nutrient itself.

When evaluating diet-disease links, do not trust absolute nutrient numbers (like grams of fat) or simple percentages (nutrient density) if total calories vary between groups. Instead, use statistical methods (like regression residuals) to isolate the nutrient's effect independent of total energy intake. If a nutrient's association with disease disappears after adjusting for calories, the nutrient itself is likely not the primary cause.

Early and aggressive LDL cholesterol lowering in Familial Hypercholesterolemia (FH) patients significantly reduces cumulative LDL burden and prevents premature coronary heart disease (CHD).

If you or your child has Familial Hypercholesterolemia (FH), do not wait for symptoms. Start maximal statin therapy immediately upon diagnosis to lower LDL cholesterol to specific targets (e.g., <100 mg/dL for adults). This prevents the cumulative damage that leads to heart attacks in your 30s or 40s. Combine medication with lifestyle changes (diet, exercise, no smoking).

In humans, insulin resistance in muscle is primarily caused by intracellular accumulation of fatty acid metabolites (diacylglycerol, ceramides) which activate serine/threonine kinases (e.g., PKC-theta), leading to impaired insulin signaling and reduced glucose transport, rather than by the Randle glucose-fatty acid cycle mechanism.

Insulin resistance in muscle is driven by lipid intermediates like diacylglycerol interfering with insulin signaling, not just by fat oxidation. Managing this involves improving how the body partitions fat away from muscle and liver, potentially through agents that promote adipocyte differentiation or improve mitochondrial fatty acid metabolism.

Nonalcoholic fatty liver disease (NAFLD) is characterized by significant hepatic and peripheral insulin resistance, independent of obesity or glucose tolerance, effectively making it a feature of the metabolic syndrome.

If you have NAFLD, even if you are not overweight or have normal blood sugar, your body likely processes insulin poorly. This insulin resistance is a key driver of the liver condition and places you in the metabolic syndrome category, requiring attention to metabolic health beyond just weight management.

Dietary (poly)phenolic compounds exert protective effects against chronic diseases (cardiovascular, neurodegeneration, cancer) primarily through their phase II metabolites and colonic catabolites, rather than the parent compounds found in food.

Eat a variety of (poly)phenol-rich foods like berries, tea, coffee, and cocoa. The health benefits are real, but they likely come from how your body and gut bacteria break these down into active metabolites, not from the original plant compounds circulating in your blood. Don't expect high-dose supplements of the parent compound to work like the whole food.

Insulin resistance directly causes cardiovascular disease through three primary mechanisms: signal transduction alteration, impaired substrate metabolism regulation, and altered substrate delivery to the myocardium.

If you have insulin resistance (often associated with obesity or type 2 diabetes), you are at higher risk for heart disease regardless of your cholesterol levels. Addressing insulin sensitivity through lifestyle changes is critical for heart health.

Insulin resistance leads to endothelial dysfunction by selectively impairing nitric oxide (NO) production while activating pro-inflammatory and pro-thrombotic pathways, contributing to hypertension and atherosclerosis.

Insulin resistance damages the lining of your blood vessels (endothelium) by reducing nitric oxide production. This leads to higher blood pressure and increased risk of heart disease. Improving insulin sensitivity helps protect your blood vessels.

Cardiovascular disease (CVD) affects approximately 32.2% of adults with Type 2 Diabetes Mellitus (T2DM) globally, with coronary artery disease (21.2%) and atherosclerosis (29.1%) being the most prevalent comorbidities, while stroke is the least prevalent (7.6%).

If you have Type 2 Diabetes, your risk of cardiovascular disease is significantly higher than the general population, affecting roughly 1 in 3 people in this group. The most common heart issues are coronary artery disease and atherosclerosis. To mitigate this, focus on a comprehensive strategy: control blood sugar, quit smoking, manage blood pressure, treat cholesterol, and maintain a healthy weight. This is not just about sugar; it is about overall heart health.

Cardiovascular disease is the primary cause of mortality in Type 2 Diabetes, accounting for approximately 50.3% of all deaths in this population, with coronary artery disease and stroke being the major contributors.

For people with Type 2 Diabetes, heart disease is not just a complication; it is the leading cause of death, responsible for half of all fatalities. Preventing heart disease is the most critical step for extending life expectancy. This involves aggressive management of blood pressure, cholesterol, and blood sugar, alongside lifestyle changes like smoking cessation and exercise.

In individuals with type 2 diabetes and obesity, skeletal muscle mitochondria exhibit reduced functional capacity (Complex I activity) and smaller morphological size, which correlates with the severity of insulin resistance.

If you have type 2 diabetes or obesity, your muscle mitochondria may be less efficient at burning fuel, contributing to insulin resistance. This is not just a 'willpower' issue but a biological one. However, because this dysfunction correlates with insulin resistance, interventions that improve metabolic health (like exercise, which increases mitochondrial biogenesis) can potentially reverse or mitigate these structural and functional deficits.

Butyrate maintains anaerobic conditions in the colon by activating PPARγ and repressing inducible nitric oxide synthase (iNOS), which prevents the proliferation of pathogenic facultative anaerobes like Enterobacteriaceae.

Maintain a healthy gut barrier by ensuring adequate butyrate production. Butyrate, a short-chain fatty acid produced by bacteria from fiber, activates PPARγ in colon cells to limit oxygen diffusion and repress inflammatory enzymes (iNOS). This creates an anaerobic environment that suppresses pathogenic bacteria like Enterobacteriaceae. Prioritize dietary fibers that promote butyrate production, such as resistant starches.

Metabolic endotoxaemia, characterized by elevated circulating lipopolysaccharides (LPS) due to increased gut permeability, drives low-grade chronic inflammation associated with type 2 diabetes, NAFLD, and obesity.

High-fat diets can increase gut permeability, allowing lipopolysaccharides (LPS) from Gram-negative bacteria to enter the bloodstream. This triggers a low-grade inflammatory response via Toll-like receptors, contributing to insulin resistance and metabolic diseases like type 2 diabetes and NAFLD. Managing fat intake and supporting gut barrier integrity are key to reducing this inflammatory burden.

Faecal Microbiota Transplantation (FMT) from lean donors to individuals with metabolic syndrome can significantly increase insulin sensitivity and butyrate production, establishing a causal link between microbiota composition and host glucose homeostasis.

FMT from lean donors is a potent intervention for improving insulin sensitivity in metabolic syndrome, primarily by boosting butyrate-producing bacteria. It is currently a medical procedure, not a consumer product.

Gut dysbiosis, characterized by reduced bacterial diversity and butyrate production, contributes to the pathogenesis of liver diseases (NAFLD, NASH, Alcoholic Liver Disease, PSC) through the translocation of bacterial products (endotoxins) to the liver, triggering inflammation.

Maintaining gut barrier integrity and microbial diversity is crucial for liver health. Probiotics and dietary fiber may help reduce liver inflammation by preventing the translocation of bacterial endotoxins to the liver.

AdipoQ (adiponectin) mRNA expression is significantly down-regulated in adipose tissue from obese humans and obese mice compared to lean controls.

This paper identifies that adiponectin (AdipoQ) levels drop significantly in obesity. While this paper does not offer a treatment, it establishes that obesity is associated with a specific hormonal deficit, suggesting that restoring these levels might be a therapeutic target.

Diet-induced weight loss triggers a significant increase in 24-hour plasma ghrelin levels, acting as a hormonal adaptive response to energy deficit.

When you lose weight through dieting, your body biologically fights back by increasing ghrelin, a hormone that drives hunger. This is a normal adaptive response, not a failure of willpower. Expect increased hunger as a physiological signal of your energy deficit.

Gastric bypass surgery results in abnormally low plasma ghrelin levels and the loss of normal meal-related ghrelin fluctuations, which may contribute to sustained weight loss.

Gastric bypass surgery uniquely suppresses ghrelin, the hunger hormone, and eliminates its normal meal-time spikes. This hormonal suppression, rather than just stomach size reduction, helps explain why patients often feel less hungry and maintain weight loss better than with dieting alone.

Obesity-induced expansion of white adipose tissue leads to local hypoxia, which triggers the transcription factor HIF-1 and subsequent secretion of pro-inflammatory adipokines (e.g., TNF-alpha, IL-6, PAI-1), contributing to insulin resistance and metabolic syndrome.

This research suggests that as fat tissue grows, it can outgrow its blood supply, creating low-oxygen conditions that trigger inflammation. This inflammation worsens insulin resistance. Therefore, interventions that reduce fat mass or improve vascular health in adipose tissue may help break this cycle of inflammation and metabolic dysfunction.

Adipose tissue directly secretes pro-inflammatory cytokines (TNF-alpha, IL-6) and acute-phase proteins (PAI-1, haptoglobin) in obesity, contributing to elevated circulating levels and metabolic comorbidities.

Fat tissue is not just inert storage; it actively releases inflammatory proteins that harm metabolic health. Reducing fat mass can reduce this source of inflammation.